Ultragenyx Pharm Stock Price, News & Analysis

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has announced the pricing of an underwritten public offering of 4,444,444 shares at $90.00 per share, aiming to raise approximately $400 million in gross proceeds. The offering's close is anticipated around November 2, 2020, subject to customary closing conditions. Underwriters include J.P. Morgan, Goldman Sachs, BofA Securities, and Cowen, with an option to purchase an additional 666,666 shares. This strategic capital raise aligns with the company's commitment to developing therapies for rare genetic diseases.

Ultragenyx Pharmaceutical (NASDAQ:RARE) announced a public offering of up to $400 million in common stock, with an option for underwriters to purchase an additional $60 million within 30 days. The offering is subject to market conditions and does not guarantee completion. Major banks involved include J.P. Morgan, Goldman Sachs, BofA Securities, and Cowen. The funds raised will be utilized for the development of therapies aimed at serious rare genetic diseases, reinforcing Ultragenyx's commitment to addressing high unmet medical needs.

Ultragenyx Pharmaceutical reported Q3 2020 revenues of $81.5 million, with Crysvita generating $37.3 million. The company raised the lower end of its Crysvita revenue guidance to $130 million from $125 million, with a total expected range of $130 million to $140 million. The launch of Dojolvi yielded $3.9 million in sales. However, operating expenses were $131.8 million, leading to a net loss of $68.8 million for the quarter. Notably, the interim data for GTX-102 shows promise for Angelman Syndrome, though serious adverse events were reported.

GeneTx Biotherapeutics and Ultragenyx Pharmaceutical (NASDAQ: RARE) announced positive interim data from the Phase 1/2 study of GTX-102, an investigational treatment for Angelman syndrome. All five patients treated showed significant improvements in communication, behavior, and motor functions by day 128. However, serious adverse events related to lower extremity weakness were noted at the highest doses, prompting a pause in dosing. The study protocol will be amended to lower dosages and minimize side effects. Further data will be presented at the FAST Global Summit in December 2020.

Ultragenyx Pharmaceutical and Solid Biosciences announced a strategic collaboration to develop gene therapies for Duchenne muscular dystrophy. The agreement includes a $40 million upfront investment from Ultragenyx, with potential milestone payments totaling up to $255 million and tiered royalties. Solid retains exclusive rights to its microdystrophin technology for other uses. The collaboration aims to harness Solid's microdystrophin construct and Ultragenyx’s HeLa PCL platform to enhance treatment efficacy. The partnership is positioned to leverage both companies' strengths in advancing therapies for rare diseases.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced a conference call scheduled for October 27, 2020, at 5 PM ET to discuss its third quarter 2020 financial results and provide a corporate update. The call will be accessible via the company's website, and participants can join by phone. Ultragenyx focuses on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases, aiming for efficient drug development to address high unmet medical needs.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announces CEO Emil D. Kakkis will present virtually at the Jefferies Virtual Gene Therapy/Editing Summit on October 2, 2020, at 1:00 PM ET. The presentation will be accessible live and as an archive on their website. Ultragenyx focuses on developing treatments for serious rare and ultra-rare genetic diseases, with a commitment to efficient drug development. They aim to provide safe and effective therapies to patients with high unmet medical needs. Visit their website for more details.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at three upcoming investor conferences. The events include the Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020, the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15, 2020, and the BofA Securities Virtual Global Healthcare Conference on September 16, 2020. Live and archived webcasts of these presentations will be available on the company’s website for 90 days.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer, effective November 2, 2020. Dier will oversee corporate finance, strategy, investor relations, corporate communications, and information technology. She joins from Portola Pharmaceuticals, where she served as CFO, enhancing her experience in financial leadership. Ultragenyx aims to grow its commercial opportunities and pipeline for rare diseases, while thanking outgoing CFO Shalini Sharp for her contributions.